288 related articles for article (PubMed ID: 16337408)
21. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
22. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
Bancroft EK; Locke I; Ardern-Jones A; D'Mello L; McReynolds K; Lennard F; Barbachano Y; Barwell J; Walker L; Mitchell G; Dorkins H; Cummings C; Paterson J; Kote-Jarai Z; Mitra A; Jhavar S; Thomas S; Houlston R; Shanley S; Eeles RA
J Med Genet; 2010 Jul; 47(7):486-91. PubMed ID: 20472659
[TBL] [Abstract][Full Text] [Related]
23. BCoR-L1 variation and breast cancer.
Lose F; Arnold J; Young DB; Brown CJ; Mann GJ; Pupo GM; ; Khanna KK; Chenevix-Trench G; Spurdle AB
Breast Cancer Res; 2007; 9(4):R54. PubMed ID: 17697391
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families.
Gerdes AM; Cruger DG; Thomassen M; Kruse TA
Clin Genet; 2006 Feb; 69(2):171-8. PubMed ID: 16433698
[TBL] [Abstract][Full Text] [Related]
25. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Farshid G; Balleine RL; Cummings M; Waring P;
Am J Surg Pathol; 2006 Nov; 30(11):1357-66. PubMed ID: 17063074
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
27. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
28. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
[TBL] [Abstract][Full Text] [Related]
29. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Silva E; Gatalica Z; Snyder C; Vranic S; Lynch JF; Lynch HT
Breast J; 2008; 14(1):14-24. PubMed ID: 18086271
[TBL] [Abstract][Full Text] [Related]
30. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.
Shannon KM; Lubratovich ML; Finkelstein DM; Smith BL; Powell SN; Seiden MV
Cancer; 2002 Jan; 94(2):305-13. PubMed ID: 11900216
[TBL] [Abstract][Full Text] [Related]
31. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
[TBL] [Abstract][Full Text] [Related]
32. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
[TBL] [Abstract][Full Text] [Related]
33. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
34. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
35. [Management of gynecological tumors associated with BRCA1 and BRCA2 germline mutations. Case report and literature review].
Fruscalzo A; Lellé RJ; Calcagno A; Driul L; Damante G; Marchesoni D
Minerva Ginecol; 2006 Apr; 58(2):171-5. PubMed ID: 16582871
[TBL] [Abstract][Full Text] [Related]
36. [Preventive surgical prcedures for inherited risk of breast cancer].
Menke-Pluymers MB; Seynaeve C; van Geel AN; Klijn JG; Meijers-Heijboer EJ; Eggermont AM
Ned Tijdschr Geneeskd; 2005 Nov; 149(48):2663-7. PubMed ID: 16358615
[TBL] [Abstract][Full Text] [Related]
37. Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side.
Garber JE; Golshan M
J Clin Oncol; 2009 Dec; 27(35):5862-4. PubMed ID: 19858367
[No Abstract] [Full Text] [Related]
38. Which individuals undergoing BRACAnalysis need BART testing?
Shannon KM; Rodgers LH; Chan-Smutko G; Patel D; Gabree M; Ryan PD
Cancer Genet; 2011 Aug; 204(8):416-22. PubMed ID: 21962891
[TBL] [Abstract][Full Text] [Related]
39. [Peculiarities of diagnosis, treatment and prevention of hereditary cancer of the breast and ovary. Clinical and genetic screening among BRCA1/2 mutation carriers and individuals with high family risk of cancer].
Rumiantseva UV; Rumiantsev PO; Kiseleva MV
Vopr Onkol; 2008; 54(3):251-9. PubMed ID: 18652227
[No Abstract] [Full Text] [Related]
40. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
